Eisai To File Dacogen sNDA for Out-Patient MDS, Despite Less Than Stellar Survival Data
This article was originally published in PharmAsia News
Executive Summary
TOKYO - As part of its strategy to reinforce its oncology and innovative pharmaceutical products, Eisai July 1 said its ongoing clinical trial comparing Dacogen with best supportive care in elderly patients with myelodysplastic syndromes, a bone marrow disease, had registered results that would enable the company to submit for applying the treatment on an out-patient basis, instead of in-hospital treatment